drugset / Trial / NCT01334918

A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

NCT01334918

Phase 2 Completed 124 enrolled Astellas Pharma Inc
RandomizedCrossoverOpen-labelDiagnostic

Summary

The purpose of this study is to compare Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT) stress myocardial perfusion imaging (MPI) with regadenoson in order to detect the presence or absence of reversible defects.

Timeline

Start
2011-04-26
Primary completion
2012-07-02
Completion
2012-07-02

Drugs

EvaluationDrugModalityDoseRoute
Background Regadenoson Diagnostic / imaging agent 0.4 mg Intravenous